Program:
Fibrin Sealant has been developed as a product that induces hemostasis for bleeding in a number
of clinical settings. The drug has been available in Europe for over ten years, but is not licensed
in the United States, although it is being evaluated by the Food and Drug Administration. This
meeting will bring together clinicians who have used both plasma-pool derived and autologous
fibrin sealants in the U.S., international treaters who have used commercial products available in
Europe, scientists who have used non-fibrin based tissue sealants, and investigators who have
developed new uses for fibrin sealant. This meeting will focus on many of the exciting new
applications for plasma derived fibrin sealants. New applications and formats of fibrin sealant
for hemostasis will be discussed. Recently, fibrin sealant has been utilized as an adhesive,
biocompatible delivery matrix for growth factors, chemotherapeutic agents, bone inducing
materials, collagen, antibiotics and a variety of other materials. The clinical uses of fibrin
sealant as hemostatic agents in thoracic, plastic/burn, abdominal, cardiovascular and
neurosurgery will be presented and discussed. Finally, the issues which relate to the testing and
licensure of the product will each be discussed during a half day panel discussion.
Registration :
For information: Cambridge Symposia
1037 Chestnut Street
Newton Upper Falls, MA 02164
Phone: 617-630-1399
Fax: 617-630-1395
Deadline for Abstracts: December 6, 1995
Email for Requests and Registration: symposia@xensei.com